Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma.

Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE.

Clin Cancer Res. 2016 Jul 15;22(14):3550-9. doi: 10.1158/1078-0432.CCR-15-1698. Epub 2016 Mar 2.

PMID:
26936915
2.

UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation.

Du C, Wu H, Leng RP.

Oncotarget. 2016 Jan 19;7(3):2823-36. doi: 10.18632/oncotarget.6555.

3.

Human bronchial epithelial BEAS-2B cells, an appropriate in vitro model to study heavy metals induced carcinogenesis.

Park YH, Kim D, Dai J, Zhang Z.

Toxicol Appl Pharmacol. 2015 Sep 15;287(3):240-5. doi: 10.1016/j.taap.2015.06.008. Epub 2015 Jun 17.

PMID:
26091798
4.

Gene expression profile of human lung epithelial cells chronically exposed to single-walled carbon nanotubes.

Chen D, Stueckle TA, Luanpitpong S, Rojanasakul Y, Lu Y, Wang L.

Nanoscale Res Lett. 2015 Jan 27;10:12. doi: 10.1186/s11671-014-0707-0. eCollection 2015.

5.

Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters.

Loughery J, Cox M, Smith LM, Meek DW.

Nucleic Acids Res. 2014 Jul;42(12):7666-80. doi: 10.1093/nar/gku501. Epub 2014 Jun 13.

6.

Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells.

Shi X, Liu J, Ren L, Mao N, Tan F, Ding N, Yang J, Li M.

BMB Rep. 2014 Apr;47(4):221-6.

7.

Differential responses to genotoxic agents between induced pluripotent stem cells and tumor cell lines.

Lu Y, Xu D, Zhou J, Ma Y, Jiang Y, Zeng W, Dai W.

J Hematol Oncol. 2013 Sep 20;6(1):71. doi: 10.1186/1756-8722-6-71.

8.

Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2.

Cao JY, Shire K, Landry C, Gish GD, Pawson T, Frappier L.

Mol Cell Biol. 2014 Jan;34(2):246-58. doi: 10.1128/MCB.00968-13. Epub 2013 Nov 11.

9.

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.

Albert TK, Rigault C, Eickhoff J, Baumgart K, Antrecht C, Klebl B, Mittler G, Meisterernst M.

Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.

10.

DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase.

Douarre C, Mergui X, Sidibe A, Gomez D, Alberti P, Mailliet P, Trentesaux C, Riou JF.

Nucleic Acids Res. 2013 Apr 1;41(6):3588-99. doi: 10.1093/nar/gkt073. Epub 2013 Feb 8.

11.

Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.

Furlan A, Lamballe F, Stagni V, Hussain A, Richelme S, Prodosmo A, Moumen A, Brun C, Del Barco Barrantes I, Arthur JS, Koleske AJ, Nebreda AR, Barilà D, Maina F.

J Hepatol. 2012 Dec;57(6):1292-8. doi: 10.1016/j.jhep.2012.07.044. Epub 2012 Aug 10.

12.

The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G₁ arrest.

Bennett RL, Pan Y, Christian J, Hui T, May WS Jr.

Cell Cycle. 2012 Jan 15;11(2):407-17. doi: 10.4161/cc.11.2.18999. Epub 2012 Jan 15.

13.

TP53 status and response to treatment in breast cancers.

Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A.

J Biomed Biotechnol. 2011;2011:284584. doi: 10.1155/2011/284584. Epub 2011 May 9. Review.

14.

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S.

Oncotarget. 2010 Nov;1(7):639-50.

15.

Hexavalent chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation of Bcl-2 members, ERK1/2 and p53.

Banu SK, Stanley JA, Lee J, Stephen SD, Arosh JA, Hoyer PB, Burghardt RC.

Toxicol Appl Pharmacol. 2011 Mar 15;251(3):253-66. doi: 10.1016/j.taap.2011.01.011. Epub 2011 Jan 22.

Items per page

Supplemental Content

Write to the Help Desk